Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature-Reference-Cited by-同舟云学术

Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature

Published:2024-05-16 Issue:7 Volume:43 Page:1475-1480
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Lafon-Desmurs Barthelemy,Gachet Benoit,Hennart Benjamin,Valentin Benjamin,Roosen Gabrielle,Degrendel Maxime,Loiez Caroline,Beltrand Eric,D’Elia Piervito,Migaud Henri,Robineau Olivier,Senneville Eric

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10096-024-04849-0.pdf

Reference29 articles.

1. Smeds MR, Duncan AA, Harlander-Locke MP, Lawrence PF, Lyden S, Fatima J et al (2016) Treatment and outcomes of aortic endograft infection. J Vasc Surg févr 63(2):332–340

2. Bosco F, Cacciola G, Giustra F, Risitano S, Capella M, Vezza D, Barberis L, Cavaliere P, Massè A, Sabatini L (2023) Characterizing recurrent infections after one-stage revision for periprosthetic joint infection of the knee: a systematic review of the literature. Eur J Orthop Surg Traumatol 33(7):2703–2715. https://doi.org/10.1007/s00590-023-03480-7

3. Zhang C, Liu Z, Lin Y, Cai Y, Zhang X, Huang Z et al (2022) Patient-reported outcome on quality of life and pain after revision arthroplasty for periprosthetic joint infection: A cross-sectional study. J Clin Med 11(23):7182

4. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis janv 56(1):e1-25

5. Pouderoux C, Becker A, Goutelle S, Lustig S, Triffault-Fillit C, Daoud F et al (2019) Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients. J Antimicrob Chemother 74(7):2060–4